For aseptic filling of suxamethonium chloride into Type I borosilicate vials, the API is dissolved in Water for Injections and adjusted with hydrochloric acid to pH 3.5–4.5. This pH window retards ester hydrolysis while maintaining tolerable injection-site properties. Sodium chloride is added to achieve isotonicity at 0.9% w/v. Terminal steam sterilisation at 121 °C for 15 minutes is not used for this molecule because the ester linkage undergoes accelerated hydrolysis above pH 5.0 and at elevated temperatures. The resulting degradation products, choline chloride and succinic acid, shift pH downward and reduce potency. Aseptic filtration through 0.22 μm polyethersulfone cartridges is therefore the terminal sterilisation step. On production lines using rotary piston fillers, fill-volume accuracy is maintained within ±2.0% for 10 mL vials and ±1.5% for 20 mL vials under EU GMP Annex 1 aseptic-processing requirements. Filter integrity is tested before and after filling by bubble point or diffusive flow in accordance with ASTM F838-20. In-process checks include pH by USP <791>, osmolality by USP <785>, and sub-visible particulate counts by Ph. Eur. 2.9.19. The solution is incompatible with alkaline dilution and with barbiturate sodium salts. Mixing with thiopental sodium in the same intravenous line produces visible precipitation. Equine and bovine anesthesia protocols employ this injection for rapid-sequence induction before endotracheal intubation. Clinical blockade is monitored by train-of-four peripheral nerve stimulation. Onset and recovery are influenced by cardiac output, body temperature, and plasma cholinesterase activity. Published data for breed-specific veterinary differences is limited, so dose titration is performed by the attending veterinarian.

When Short-Acting Neuromuscular Blockade Is Required in Equine Induction Protocols

In equine anesthesia, the decision to use suxamethonium chloride is governed by the need for rapid skeletal muscle relaxation without prolonged recumbency. The compound produces a depolarising block at the motor endplate. Initial fasciculations precede flaccid paralysis, which is distinct from the non-depolarising profile of atracurium or rocuronium. Because plasma butyrylcholinesterase rapidly hydrolyses the ester, the duration of action is short. Equine protocols require preoxygenation, patent venous access, and immediate availability of a mechanical ventilator. Endotracheal intubation is performed once jaw relaxation is adequate. Monitoring includes capnography, pulse oximetry, and peripheral nerve stimulation. The main operational boundary is that suxamethonium should not be administered to animals with known hyperkalemia, severe metabolic acidosis, or suspected malignant hyperthermia. The first-dose response may be potentiated by prior organophosphate exposure or cholinesterase inhibition. Injectable solutions at 20 mg/mL are diluted only with 0.9% sodium chloride injection. Dilution with lactated Ringer’s solution is avoided because electrolyte shifts and pH alteration can destabilise the active moiety. Hypothermia prolongs neuromuscular blockade because plasma cholinesterase activity declines with decreasing body temperature. Published field reports for bovine use are less consistent than those for equine use; published data on breed-specific plasma cholinesterase variance is limited. This limitation is managed clinically by incremental dosing rather than fixed bodyweight protocols.

Why Tablet and Capsule Presentations of Suxamethonium Chloride Fail Pharmacokinetically

Because the bis-quaternary ammonium structure prevents passive diffusion across intestinal membranes, oral administration of suxamethonium chloride does not yield a clinically useful neuromuscular block. The ester bond is hydrolysed by butyrylcholinesterase present in plasma, liver, and intestinal mucosa. Any fraction reaching the portal circulation is further cleared before systemic distribution. No pharmacopoeial monograph supports oral tablets or capsules for this API. Published data for this specific configuration is limited, but the absence of oral products across regulatory jurisdictions is consistent with negligible oral bioavailability. Formulation of tablets or capsules for oral use is therefore not recommended. Excipients that raise local pH, such as sodium bicarbonate disintegrants, accelerate hydrolytic degradation in the dosage form itself. Enteric coating cannot overcome enzymatic hydrolysis in plasma. The rationale for oral dosage forms is confined to exploratory pharmacokinetic work, and such work must be conducted under a recognised institutional animal care protocol.

Compounding pharmacies should not regard sachet powders or granules as interchangeable with injectable-grade API. The presence of lactose, sucrose, or other oral bulking agents increases the risk of particulate load if the powder is accidentally reconstituted for parenteral use. Capsule shells add no stabilising benefit. The operational rule is that tablet and capsule formats are not viable presentations for any therapeutic indication requiring suxamethonium chloride delivery.

When dry API powder and granules are transferred for lyophilized injection or sterile compounding, particle-size and moisture controls differ from those for non-hygroscopic actives. Suxamethonium chloride absorbs atmospheric water above 40% relative humidity, and sorbed water accelerates solid-state hydrolytic degradation. Vacuum drying at 40 °C with a nitrogen bleed is used to reduce loss on drying below 1.0%. Micronisation is generally not required because the API is freely soluble in water. De-agglomeration through a 500 μm stainless steel sieve prevents lump formation during solution preparation. Powder transfer is performed in contained isolators with relative humidity below 30% and positive-pressure HEPA-filtered air. For sterile compounding, the powder is not dry-blended with anionic excipients. Only parenteral bulking agents such as mannitol or trehalose are co-lyophilised. Wet granulation with aqueous binders is contraindicated because the binder solution initiates hydrolysis before drying can be completed. Dry blending of suxamethonium chloride with directly compressible diluents for oral tablets carries the same contraindication as all oral formats and does not form part of current veterinary manufacturing practice.

Granulation in high-shear mixers using non-aqueous solvents has been evaluated in exploratory pharmaceutical development. Published data for this specific configuration is limited. The bis-quaternary structure is stable in dry solid form only when moisture is rigorously excluded. Stainless steel contact surfaces should be passivated; free iron accelerates ester hydrolysis in the presence of residual moisture. This is not a routine formulation route but is relevant when a manufacturer audits a potential site for API powder handling.

Lyophilized Cake Reconstitution Parameters and Collapse Temperature Boundaries

A typical lyophilization cycle for suxamethonium chloride veterinary injection begins with an aqueous solution containing the API and a bulking agent. The solution is filled into vials, partially stoppered, and loaded onto temperature-controlled shelves. Primary drying is conducted below the formulation collapse temperature. Published formulation-specific collapse temperature data is limited, so freeze-drying microscopy is used for each new formulation. Equipment-dependent settings include freezing at -40 °C, followed by primary drying at -20 °C to 0 °C under a chamber pressure of 50–100 μbar. These values are validated per batch and are not universal. Residual moisture is measured by Karl Fischer titration according to USP <921>; acceptance is typically less than 2.0% w/w. Cake appearance is inspected for shrinkage, meltback, or collapse. The stopper is seated under vacuum or nitrogen. Reconstitution time is specified in the package insert and is usually less than 60 seconds with 0.9% sodium chloride injection. Reconstituted solution is used immediately because the ester hydrolyses in aqueous media. A cloudy or viscous residue after reconstitution is grounds for rejection, indicating moisture ingress or improper freezing.

Field anesthesia kits used in large-animal practice place additional stress on lyophilized vials. Vial integrity after exposure to cyclic temperature changes is evaluated by vacuum decay. Stopper moisture vapor transmission rates above 0.2 g/m²/day are not acceptable for this API in tropical field conditions. Because suxamethonium chloride is hygroscopic, the package insert specifies storage below 25 °C in a dry place. Opened vials are discarded after use. The lyophilized format is preferred over liquid solution in field environments where cold-chain continuity cannot be guaranteed, but the dry cake is not indefinitely stable. Residual moisture below 1.0% and protective nitrogen headspace maintain potency across the labelled shelf life.

Across feed premix and drinking water applications, the addition of suxamethonium chloride delivers no measurable neuromuscular blockade. The ester bond is hydrolysed in aqueous media and during feed processing, and intestinal absorption is negligible due to the quaternary ammonium structure. No regulatory agency has approved a feed premix or drinking water formulation for this compound. Premix plants using horizontal ribbon blenders cannot overcome the fundamental pharmacokinetic barrier. Residual cholinesterase activity in intestinal tissue destroys the active moiety before systemic distribution. Target animal safety demonstrations for feed premix would require therapeutic plasma concentrations that cannot be supported by published data. This is a shallow technical zone because no credible formulation path exists.

Controlling Moisture Uptake and Electrolyte Incompatibility in Compounded Solutions

Hospital compounding of suxamethonium chloride injection from API powder or from a licensed concentrate is regulated under USP <797> in the United States and under equivalent pharmacy practice standards elsewhere. The compounding environment must be an ISO Class 5 laminar airflow workbench placed inside an ISO Class 7 buffer room. Personnel verify the API certificate of analysis for endotoxin, potency, and moisture before weighing. A 0.22 μm sterile filter is used for clarification if the API is not supplied sterile. High-risk compounded sterile preparations from non-sterile API are assigned beyond-use dates of not more than 24 hours at controlled room temperature or 3 days under refrigeration under USP <797>. Because suxamethonium chloride hydrolyses in aqueous media, many veterinary hospital pharmacies apply a shorter internal beyond-use date of 8 hours at 2–8 °C when site-specific stability data is not available. This practice reflects the chemical instability of the ester rather than a compendial sterility limit.

Electrolyte incompatibility is a principal formulation constraint in compounded solutions. Calcium-containing infusion fluids should not be used as diluents because divalent cations can alter pH and accelerate hydrolytic degradation. Potassium-containing solutions are avoided in the same intravenous line because suxamethonium can raise serum potassium momentarily during depolarization. The final compounded syringe must be labelled with the exact concentration per millilitre and the beyond-use date. Infusion pumps with low-sorption tubing are recommended because quaternary ammonium compounds exhibit surface adsorption to some polyvinyl chloride sets. Published extractables data for suxamethonium chloride in PVC tubing is limited, so low-sorption polyethylene-lined tubing is used where available. These operational boundaries protect the integrity of the dose and reduce variability during short-duration neuromuscular blockade in veterinary intensive care units.